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OBJECTIVE—GAD antibodies (GADA) are more common in type 1 diabetic subjects diag-
nosed at an older age, whereas insulinoma-antigen 2 antibodies (IA-2A) are more common in
subjectswithyoungeronset.Theprevalenceofbothantibodiesdecreaseswithlongerdurationof
type 1 diabetes. We evaluated the interaction between age of diagnosis (onset) and duration of
diabetes on the percentage of GADA- and IA-2A–positive subjects.
RESEARCH DESIGN AND METHODS—Data were used from 5,020 individuals with
type1diabetesobtainedfromtheType1DiabetesGeneticsConsortiumdataset.Thepercentages
of GADA- and IA-2A–positive subjects were modeled with duration as the continuous indepen-
dent variable using a modiﬁed spline.
RESULTS—Withintheﬁrst5yearsfromdiagnosis,19.4%ofindividuals(medianage13years)
had neither GADA nor IA-2A, and by 6 to 13 years after diagnosis (median age 18 years), 31.7%
were antibody-negative. There was no signiﬁcant interaction between onset of disease and du-
ration of diabetes for IA-2A (P = 0.30). The interaction was signiﬁcant for GADA (P = 0.0002),
resulting from differences in subjects diagnosed at or older than age 14. For these individuals,
there was no apparent effect of duration of disease on the percentage of GADA-positive subjects
within the ﬁrst 5 years of diagnosis.
CONCLUSIONS—Onsetand duration of diabetes bothhaveanimportant effectonantibody
status. The interaction of onset and duration on GADA positivity, but not on IA-2A, suggests
differences in biology. These data provide a context for clinicians to interpret results of autoan-
tibody testing in clinical practice.
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D
iabetesautoantibodies(DAAs)have
been used to predict risk for type 1
diabetes and to classify individuals
with diabetes as having an immune-
mediated b-cell destructive process. At
diagnosis of type 1a diabetes, about 95%
ofindividualswillhaveoneormore auto-
antibodies, including insulin autoanti-
bodies (IAA), GAD antibodies (GADA),
insulinoma-antigen 2 antibodies (IA-2A,
also called ICA512), and the recently de-
scribed zinc transporter protein autoanti-
bodies (ZnT8Ab) (1). The frequency of
antibody positivity is known to vary
with age and to decrease with longer du-
ration of disease. For example, GADA are
more common in older subjects, whereas
IAA and IA-2A are more common in
younger individuals (2–6). About 45%
of subjects are positive for GADA or
IA-2A about 15 years from diagnosis (2).
HLA type is also associated with antibody
frequency, with GADA more common in
DR3 (7,8) individuals with type 1a diabe-
tes and IA-2A more common in DR4 in-
dividuals (7–10).
What, if any, interaction there is
between age of diagnosis and duration
of diabetes on GADA and IA-2A status
is unknown. We explored this question
using the large Type 1 Diabetes Genetics
Consortium (T1DGC) dataset of individ-
uals with type 1 diabetes who provided
blood samples for genetic analysis and
autoantibody typing. Our primary objec-
tive was to investigate the interaction of
age of diagnosis (onset) and duration of
diabetes on GADA and IA-2A status in




Data were obtained from a July 2009
download of the cross-sectional T1DGC
database. This international consortium
was designed to collect data and samples
from families with type 1 diabetes to in-
vestigate the contribution of genetics,
including HLA type, in the development
of type 1 diabetes (11). Samples and data
were obtained at multiple institutions af-
ter appropriate human subjects review
and written consent. Samples were tested
for GADA and IA-2A at the Barbara Davis
Center(Denver,CO)usingpreviouslyde-
scribed assays (12).
Two groups of families participated:
affected sib-pair (ASP) families, deﬁned
as families in which at least two non-
monozygoticsiblingshad type1diabetes,
and families in which there was a single
affected child from a population with a
low prevalence of type 1 diabetes (trios).
Affected siblings were considered eligible
for T1DGC if they were diagnosed with
type 1 diabetes before age 35 and treated
with insulin within 6 monthsof diagnosis
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ORIGINAL ARTICLEwithout subsequent discontinuation of
insulin treatment. After review by the
eligibility committee, 25 siblings with
onset after age 35 were also included.
Analysis
Associations of antibody positivity with
age at onset, duration of diabetes, and
HLA typing were estimated using logistic
regression models. Separate models were
ﬁt for GADA, IA-2A, and the occurrence
of either. Generalized estimating equa-
tionswereusedinallregressionmodelsto
account for potential correlation between
siblings. Onset and duration were cate-
gorized by tertiles. Multivariate models
wereﬁt, includingthe categoriconsetand
duration variables and interactions, along
withHLAtyping.Amodelwasalsoﬁtthat
modeled prevalence of the outcome as a
function of the categoric onset variable
and a spline function for duration. The
spline wasacontinuousfunctionthat was
linear within each tertile of duration, but
the slope of which could vary between
tertiles. The Wald test was used to calcu-
late the signiﬁcance of the terms within
each model. A nonparametric scatter plot
smootherprogram(13)wasusedtoassess
model ﬁt. Analyses were computed using
R2.11.0software(14).ValuesofP,0.05
were considered statistically signiﬁcant.
RESULTS—Complete HLA typing and
antibody data were available for 5,315
subjects. However, more than 40% of
children with duration of #3y e a r sa n d
who were diagnosed with diabetes ,2
years of age were negative for both
GADA and IA-2A (Supplementary Fig. 1).
Because this subpopulation may include
patients with monogenic diabetes, we
excluded from all subsequent analysis
295individualswhowereaged,2years
when they were diagnosed with type 1
diabetes. Data for the remaining 5,020
subjects were used in all subsequent
analysis.
The median age at diagnosis was 10
years (range 2–52). The median duration
of disease at the time of blood sampling
was 8 years (range 0–66). A total of 4,817
subjects were from ASP families, includ-
ing 157 parents, and 203 subjects with
type 1 diabetes were from trio families,
of which eight were parents. Males com-
prised 50.7% of subjects, 4,739 individ-
uals were white/Caucasian, 191 (3.8%)
were Asian, 80 (1.6%) were black/African
American, and 13 (0.3%) were PaciﬁcI s -
landers.Separateunivariateandmultivar-
iate analysis examining race are available
in the Supplementary Tables 1 and 2, re-
spectively.
Univariate analysis
GADA were more common in subjects
who were older at the time of diagnosis,
with an odds ratio (OR) of 2.57 (95% CI
2.21–3.00)inthoseaged.13yearswhen
they were diagnosed compared with the
reference group of those aged ,8 years at
diagnosis (Table 1, Fig. 1A). For IA-2A,
subjects who were diagnosed in the
middletertile(8–13years)hadsigniﬁcantly
higher rates of IA-2A positivity than those
withearlier (2–7 years) orlateronset ($14
years; Table 1, Fig. 1B). Subjects with in-
creasing duration of type 1 diabetes were
less likely to be GADA- or IA-2A–positive
(Table 1, Fig. 1C and D). GADA were pos-
itively associated with DR3 and DR4, with
the exception of DR4/X (where X is not
DR3 or DR4), which was not signiﬁcant.
IA-2A was also positively associated with
DR4 in any combination, but was nega-
tively associated with DR3/DR3 (Table 1).
GADA and/or IA-2A positivity (sub-
sequently denoted Aby
+) was an admix-
ture of the results for GADA and IA-2A
(Table1).Speciﬁcally,subjectswithonset
of diabetes at age $8 years were more
likely Aby
+ than those diagnosed when
they were younger. Aby
+ was less likely
with increasing duration of diabetes. DR3






+ included only age of on-
set and duration of disease as indepen-
dent variables (Supplementary Table 3).
Adding HLA to each of these models
(Table 2) improved the ﬁt( P , 0.0001
for each HLA-adjusted model compared
with non-HLA–adjusted model), yet had
verylittleimpactontheORfromthenon-
HLA– adjusted model (Supplementary
Table3).Incontrasttotheunivariateanal-
ysis, subjects with onset of 8 to 13 years
Table 1—Univariate analysis for GADA, IA-2A, or GADA and/or IA-2A subjects*
GADA IA-2A Aby+
Covariate N % Pos OR 95% CI % Pos OR 95% CI % Pos OR 95% CI
Onset age (years)
2–7 1,739 35.7 1 — 43.1 1 — 60.3 1 —
8–13 1,767 47.6 1.64† 1.42–1.88 53.1 1.50† 1.31–1.72 71.6 1.67† 1.44–1.92
$14 1,514 58.9 2.57† 2.21–3.00 40.6 0.90 0.78–1.04 69.4 1.50† 1.28–1.74
Duration (years)
0–5 1,842 58.6 1 — 60.4 1 — 80.6 1 —
6–13 1,541 44.8 0.57† 0.50–0.66 47.2 0.58† 0.51–0.67 68.3 0.52† 0.44–0.61
$14 1,637 35.6 0.39† 0.34–0.45 28.3 0.26† 0.22–0.30 50.6 0.25† 0.21–0.29
HLA
X/X 374 36.6 1 — 30.2 1 — 50.0 1 —
DR3/X 627 49.6 1.70‡ 1.27–2.27 26.0 0.81 0.60–1.10 57.3 1.34§ 1.01–1.78
DR3/DR3 374 57.0 2.29† 1.66–3.16 22.7 0.68§ 0.47–0.98 65.2 1.88‡ 1.36–2.59
DR3/DR4 1,847 47.9 1.59§ 1.23–2.05 49.1 2.23† 1.72–2.89 70.2 2.35† 1.83–3.02
DR4/X 1,278 41.8 1.24 0.96–1.61 56.7 3.02† 2.31–3.95 69.0 2.23† 1.72–2.89
DR4/DR4 520 52.5 1.91† 1.41–2.59 59.8 3.44† 2.52–4.68 76.3 3.23† 2.37–4.40
*Individual univariate analyses; dependent variables are GADA, IA-2A, or Aby
+, and independent variables (covariate) are either age of onset, duration of disease, or
HLAtype. Aby
+indicates those whoareGADA-and/or IA-2A–positive.%Pos,percentage ofantibody-positive subjects; X  DR3 or DR4. †P ,0.0001;‡P,0.001;
§P , 0.05.
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Tridgell and Associateswere statistically no more likely to be
IA-2A–positive than subjects with onset
of 2 to 7 years when duration was limited
to #5 years (Table 2).
Interaction of onset and duration
on antibody positivity
T h es m o o t h e dp l o t sf o rG A D A ,I A - 2 A ,
and Aby
+ are shown in Fig. 2. Figure 2A
suggests a possible interaction of onset
and duration for GADA, whereas this is
not evident for IA-2A or having at least
one antibody present (Aby
+). This was
conﬁrmed using a modiﬁed spline in
which a signiﬁcant interaction of onset
and duration was found for GADA (P =
0.0002),butnotforIA-2AorAby
+(Fig.3).
The interaction for GADA was driven
by differences in the frequency of GADA
positivity among those who were age 14
or older when diagnosed compared with
subjects who were younger at the time of
diagnosis. Speciﬁcally, for these subjects,
therewasnoapparenteffectofdurationof
disease on the percentage of GADA-
positive subjects within the ﬁrst 5 years
of diagnosis. Over the next 8 years of
duration of disease, the decline in the
percentage of GADA-positive subjects
approximately parallels that of the other
tertilesofonset.ThepercentageofGADA-
positive subjects declines more rapidly
in those who were diagnosed age 14 or
o l d e rc o m p a r e dw i t ht h o s ew h ow e r e
youngeratthetimeofdiagnosis.Remov-
ing the 365 outliers with a diabetes du-
ration of .30 years from our model
resulted in similar results (Supplementary
Fig. 2).
Others have reported that type 1 di-
abetic subjects with autoimmune thyroid
disease (15) or females (5,16) are more
likely to be GADA-positive than those
without thyroid disease and males,
respectively. Multivariate analysis, in-
cluding onset and duration of disease,
sex, and self-reported thyroid disease
conﬁrmed that GADA positivity is more
likely in those of female sex (OR 1.41
[95% CI 1.25–1.59], P , 0.0001) or
with self-reported thyroid disease (1.41
[1.15–1.72], P = 0.001). However, adjust-
ingforsexandself-reportedthyroiddisease
in the modiﬁed spline did not affect the
signiﬁcance of the interaction of onset
a n dd u r a t i o no nG A D A .
CONCLUSIONS—We explored the
frequencyofantibodypositivityasafunc-
tion of both age at diagnosis and duration
of disease to understand whether these
variables interacted; that is, whether the
loss of antibody positivity over time is
affectedbytheageatwhichtheindividual
was diagnosed with type 1 diabetes. We
found an interaction of onset and duration
Figure1—Thepercentageofantibody-positivesubjectsisaffectedbytheonsetanddurationoftype1diabetesforGADA(AandC,respectively)and
IA-2A(BandD,respectively).Onsetwaslimitedtoage$2yearsforpanelsCandD,asdescribedinthetext.Givenanincreaseinthescatter(dueto
lower numbers of subjects), the x-axis is truncated at both an onset and duration of 30 years. n,n u m b e ro fs u b j e c t s .
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GADA and IA-2A in the T1DGCofdiabetesonGADApositivity,butnoton
IA-2A positivity. Speciﬁcally, for individ-
uals who were diagnosed with diabetes at
age 14 or older, the percentage of individ-
uals positive for GADA changed little
during the ﬁrst 5 years after diagnosis, in
contrast to subjects diagnosed when they
were younger than age 14, in which the
percentage that remained GADA-positive
fellrapidlyduringthattime.Thechangein
antibody frequency was similar regardless
of age of diagnosis during the next 8 years
from onset of disease, only to decrease
more rapidly in the older subjects long
after diagnosis. Together with data indi-
cating that GADA is the most frequent
antibody reported in antibody-positive in-
dividuals with clinically apparent type 2
diabetes, our data suggest the hypothesis
that there are differences in the biology





(17), we postulated that there would
be a more rapid decrease in the percent-
age of antibody-positive subjects over
time from diagnosis among younger
subjects. Yet, this was observed only




N % Pos OR 95% CI % Pos OR 95% CI % Pos OR 95% CI
Onset age 2–7y e a r s
Duration (years)
0–5 530 45.5 1 — 61.3 1 — 76.6 1 —
6–13 644 34.8 0.62† 0.49–0.80 44.6 0.46‡ 0.36–0.59 62.3 0.47‡ 0.36–0.61
$ 14 565 27.6 0.44‡ 0.34–0.58 24.2 0.16‡ 0.12–0.21 42.7 0.20‡ 0.15–0.26
Onset age 8–13 years
Duration (years)
0–5 745 58.8 1.73 1.37–2.19 65.1 1.17 0.91–1.50 82.1 1.39§ 1.05–1.85
6–13 508 41.9 0.86 0.67–1.12 53.9 0.67§ 0.51–0.87 71.9 0.74§ 0.55–0.99
$ 14 514 37.0 0.68§ 0.52–0.88 35.0 0.30‡ 0.23–0.39 56.2 0.36‡ 0.27–0.48
Onset age $14 years
Duration (years)
0–5 567 70.5 2.99‡ 2.30–3.89 53.4 0.73§ 0.56–0.95 82.2 1.49§ 1.09–2.03
6–13 389 65.3 2.25‡ 1.69–3.00 42.7 0.42‡ 0.31–0.56 73.8 0.82 0.60–1.13
$ 14 558 42.5 0.90 0.70–1.15 26.2 0.20‡ 0.15–0.26 53.4 0.34‡ 0.26–0.45
HLA
X/X 374 36.6 1 — 30.2 1 — 50.0 1 —
DR3/X 627 49.6 1.94‡ 1.42–2.65 26.0 0.85 0.62–1.16 57.3 1.50§ 1.11–2.04
DR3/DR3 374 57.0 2.61‡ 1.84–3.70 22.7 0.68§ 0.47–0.99 65.2 2.11‡ 1.49–2.99
DR3/DR4 1,847 47.9 2.03‡ 1.54–2.69 49.1 2.75‡ 2.10–3.61 70.2 3.14‡ 2.39–4.13
DR4/X 1,278 41.8 1.40§ 1.06–1.86 56.7 3.58‡ 2.71–4.73 69.0 2.67‡ 2.02–3.54





subjects; X   DR3 or DR4. †P , 0.001; ‡P , 0.0001; §P , 0.05.
Figure 2—A smoothing function was used to plot the percentage of antibody-positive subjects within each tertile of onset, with duration as
a continuous variable for GADA (A), IA-2A (B), and Aby
+ (C). Aby
+, GADA- and/or IA-2A–positive.
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and not IA2.
Our data conﬁrm the effect of age on
t h ep r e s e n c eo fa u t o a n t i b o d i e s ,w i t h
younger subjects more likely to have
IA-2A and older subjects more likely to
haveGADA.Thenotableexceptiontothis
statement is the high frequency of sub-
jectswithneitherGADAnorIA-2Awithin
the ﬁrst 3 years of disease who were
diagnosed when they were younger than
age 2. Because samples were obtained
after individuals had been treated with
insulin, IAA were not measured. IAA are
often found in younger subjects, so it is
possible that some of these individuals do
indeedhavetype1adiabetes,whichcannot
be determined from this dataset. Alterna-
tively, some of the antibody-negative sub-
jects diagnosed at younger than age 2 may
have monogenic diabetes. Recent reports
indicate that about 1% of youth with di-
abetes have monogenic disease (18).
Several other ﬁndings extend previ-
ous reports. First, univariate analysis
found that IA-2A were most common in
subjects with onset at age 8 to 13, a
ﬁnding similar to Graham et al. (5), who
found that IA-2A was highest in individ-
uals aged 7 to 13 years. However, multi-
variate analysis adjusting for duration
failed to show a signiﬁcant difference in
thepercentofIA-2A–positivesubjectsbe-
tween those with onset at 2 to 7 years old
and those with onset of 8 to 13 years old
when duration was #5y e a r s .O u rﬁnd-
ings of a positive association of IA-2A
with DR4 and a negative association of
IA-2A with DR3 are consistent with
most previous reports. Despite this rela-
tionship, we found minimal to no impact
on the ORs for antibody status by age at
diagnosis and duration of disease when
HLA was included in the models.
Althoughcross-sectionalandnotlon-
gitudinal, with more than 5,000 individ-
uals with type 1 diabetes, including a
widevariationintheirageofonsetandthe
duration of disease at the time of blood
sampling, this T1DGC dataset has con-
siderable power to investigate the rela-
tionships described. Moreover, the data
presented provide an important context
for clinicians and investigators using au-
toantibody measurements to classify in-
dividuals with diabetes. With the caveat
that this study measured only GADA and
IA-2A, in clinical practice these are the
most frequently ordered tests, either as
a routine measure or to clarify diagnosis
when the clinician is confronted with
an “atypical” case, including an over-
weight child with diabetes or in cases
of suspected monogenic diabetes.
Current guidelines recommend ge-
netic screening for monogenic diabetes
when various criteria are met, including
the absence of DAAs (19). As can be seen
fromTable1,withintheﬁrst 5 years from
diagnosis, about 20% of individuals, re-
gardless of their age at diagnosis, had nei-
ther GADA nor IA-2A, and by 6 to 13
years after diagnosis, almost 40% were
antibody-negative. These data serve as a
reminder of the limitations of autoanti-
body screening for clinical classiﬁcation
in routine clinical care. Inappropriately
interpreting a negative autoantibody test
as ruling out type 1a diabetes may result
inincorrect treatments,expensivegenetic
testing, and/or failure to recommend par-
ticipation in autoantibody screening
studies to identify family members at
risk for disease.
In summary, age at diagnosis and
duration of disease both have an impor-
tant impact on autoantibody status and
should be considered when interpreting
a result in individuals with diabetes. The
impact of duration of disease on the fre-
quency of IA-2A positivity was similar
regardlessoftheageofdiagnosis,whereas
for GADA, individuals who were diag-
nosed at age 14 or older had a different
pattern than subjects who were younger
at thetimeofdiagnosis. These datasuggest
that there may be differences in the un-
derlyingbiologythatresultsinmeasureable
GADAversusIA-2A antibodies.Additional
longitudinal studies would be required to
conﬁrm these ﬁndings.
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